Sökning: (WFRF:(Vahatalo I.)) >
Long-Term Use of Sh...
Long-Term Use of Short-Acting beta(2)-Agonists in Patients With Adult-Onset Asthma
-
Vahatalo, I. (författare)
-
Lehtimaki, L. (författare)
-
Tuomisto, L. E. (författare)
-
visa fler...
-
Karjalainen, J. (författare)
-
Niemela, O. (författare)
-
Ilmarinen, P. (författare)
-
- Kankaanranta, Hannu, 1967 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Krefting Research Centre,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2022
- 2022
- Engelska.
-
Ingår i: Journal of Allergy and Clinical Immunology-in Practice. - : Elsevier BV. - 2213-2198. ; 10:8
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Short-term studies have associated high use of short-acting beta(2)-agonists (SABA) with increased risk of exacerbations, emergency visits, and asthma-related costs. However, no studies exist on long-term SABA use, and previous studies on the topic have not included information about adherence to inhaled corticosteroids (ICS) nor disease control, both affecting the need of SABA. OBJECTIVE: To evaluate the clinical characteristics of SABA and ICS usage in newly diagnosed adult-onset asthma patients during a 12-year follow-up period. METHODS: In the Seinajoki Adult Asthma Study, 203 patients with adult-onset asthma were followed for 12 years. Information on dispensed SABA and ICS during the follow-up was obtained from the Finnish Social Insurance Institution. High SABA use was defined as >= 36 canisters in 12 years, corresponding to an average of >= 3 dispensed canisters/y. RESULTS: Patients were dispensed median 6 (interquartile range: 3-16) SABA canisters and 48 (18-67) ICS canisters over 12 years, corresponding to 2 (1-4) and 11 (5-16) puffs/week, respectively. Only 10% of the patients were classified as high SABA users during this period. Obesity (body mass index >= 30) and high Airways Questionnaire 20 symptom scores at baseline predicted high long-term SABA use (incidence rate ratio: 1.53 [1.01-2.30] and 1.04 [1.00-1.08], respectively). High SABA users had higher ICS adherence, higher blood neutrophil counts, more comorbidities, and used more oral corticosteroid and antibiotic courses versus low SABA users. CONCLUSION: High SABA use was infrequent in patients with confirmed adult-onset asthma. However, as high SABA use is associated with more severe asthma, these patients should be recognized in clinical practice. (C) 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- Asthma
- Adult-onset
- Reliever therapy
- Short-acting beta(2)-agonists
- Asthma treatment
- Asthma control
- Obesity
- Prognosis
- Long-term
- Follow-up
- beta-agonist use
- inhaled corticosteroids
- medication adherence
- patterns
- remission
- exacerbations
- comorbidities
- phenotypes
- risk
- Allergy
- Immunology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas